Therapeutic targets in chronic myeloid leukaemia.
作者： Nicholas B. Heaney , Tessa L. Holyoake
DOI: 10.1002/HON.813
关键词: Imatinib mesylate 、 Cancer research 、 Chronic myeloid leukaemia 、 Hematopoietic stem cell transplantation 、 Granulocyte macrophage colony-stimulating factor 、 Immunology 、 Granulocyte colony-stimulating factor 、 Pharmacotherapy 、 Oncogene 、 Medicine 、 Stem cell
摘要: Chronic myeloid leukaemia (CML) is a clonal disorder of the haemopoietic stem cell arising as consequence formation bcr-abl oncogene. The particular molecular basis this condition has enabled development therapies that selectively target diseased cells. success rationally designed first-line therapy imatinib mesylate (IM) tempered by problems disease persistence and resistance. Novel strategies have been identified to take forward in CML these will be discussed review. This work generated from review published literature contains insight into performed our group field.
core.ac.uk
sci-hub.se 参考文章(86)
Tessa Holyoake, Xiaoyan Jiang, Connie Eaves, Allen Eaves, Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood. ,vol. 94, pp. 2056- 2064 ,(1999) , 10.1182/BLOOD.V94.6.2056
Enrique J. Andreu, Elisa Lledó, Enric Poch, Carmen Ivorra, M. Pilar Albero, José Angel Martínez-Climent, Cristina Montiel-Duarte, José Rifón, Javier Pérez-Calvo, Cristina Arbona, Felipe Prósper, Ignacio Pérez-Roger, BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Research. ,vol. 65, pp. 3264- 3272 ,(2005) , 10.1158/0008-5472.CAN-04-1357
Paolo Vigneri, Jean Y. J. Wang, Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR–ABL tyrosine kinase Nature Medicine. ,vol. 7, pp. 228- 234 ,(2001) , 10.1038/84683
M S Holtz, S J Forman, R Bhatia, Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia. ,vol. 19, pp. 1034- 1041 ,(2005) , 10.1038/SJ.LEU.2403724
Girija Dasmahapatra, Mohamed Rahmani, Paul Dent, Steven Grant, The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism Blood. ,vol. 107, pp. 232- 240 ,(2006) , 10.1182/BLOOD-2005-06-2302
J. Y. Reuther, G. W. Reuther, D. Cortez, A. M. Pendergast, A. S. Baldwin Jr., A requirement for NF-κB activation in Bcr–Abl-mediated transformation Genes & Development. ,vol. 12, pp. 968- 981 ,(1998) , 10.1101/GAD.12.7.968
Julia Thomas, Lihui Wang, Richard E. Clark, Munir Pirmohamed, Active Transport of Imatinib into and Out of Cells: Implications for Drug Resistance Blood. ,vol. 104, pp. 3739- 3745 ,(2004) , 10.1182/BLOOD-2003-12-4276
Melissa S. Holtz, Marilyn L. Slovak, Feiyu Zhang, Charles L. Sawyers, Stephen J. Forman, Ravi Bhatia, Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood. ,vol. 99, pp. 3792- 3800 ,(2002) , 10.1182/BLOOD.V99.10.3792
A Kumatori, K Tanaka, N Inamura, S Sone, T Ogura, T Matsumoto, T Tachikawa, S Shin, A Ichihara, Abnormally high expression of proteasomes in human leukemic cells. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 87, pp. 7071- 7075 ,(1990) , 10.1073/PNAS.87.18.7071
Deborah White, Verity Saunders, A. Bruce Lyons, Susan Branford, Andrew Grigg, L. Bik To, Timothy Hughes, In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML Blood. ,vol. 106, pp. 2520- 2526 ,(2005) , 10.1182/BLOOD-2005-03-1103